autologous cd34+pbsc, transduced with a lentiviral vector (-889itga2b-bddfviii-wpts(mut6)(vsvg)
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2019 (NCT03818763)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05265767 | Phase 1 | Apr 1, 2022 | Christian Medical College, Vellore, India |
| NCT03818763 | Phase 1 | Jul 1, 2019 | Medical College of Wisconsin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Christian Medical College, Vellore, India | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1